← Back to Screener
Trinity Biotech plc (TRIB)
Price$0.74
Favorite Metrics
Price vs S&P 500 (26W)-37.76%
Price vs S&P 500 (4W)6.98%
Market Capitalization$13.89M
All Metrics
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)281.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.80%
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)-9.78%
Gross Margin (TTM)33.81%
Net Profit Margin (TTM)-73.83%
EPS (TTM)$-0.11
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-0.11
Revenue Growth (5Y)-7.41%
EPS (Annual)$-0.09
ROI (Annual)-27.05%
Gross Margin (Annual)34.83%
Net Profit Margin (5Y Avg)-32.93%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)16.15%
ROA (Last FY)-30.78%
Revenue Growth TTM (YoY)-15.76%
EBITD / Share (TTM)$-0.07
ROE (5Y Avg)-161.55%
Operating Margin (TTM)-48.79%
Cash Flow / Share (Annual)$-0.47
P/B Ratio2.09x
P/B Ratio (Quarterly)3.37x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.53x
Net Interest Coverage (TTM)-2.21x
ROA (TTM)-36.43%
EV / EBITDA (TTM)85.67x
EPS Incl Extra (Annual)$-0.09
Current Ratio (Annual)1.28x
Quick Ratio (Quarterly)0.41x
3-Month Avg Trading Volume2.29M
52-Week Price Return38.04%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)0.23x
Asset Turnover (Annual)0.60x
52-Week High$3.44
Operating Margin (5Y Avg)-21.60%
EPS Excl Extra (Annual)$-0.09
CapEx CAGR (5Y)-3.22%
Tangible BV CAGR (5Y)-67.56%
26-Week Price Return-29.01%
Quick Ratio (Annual)0.62x
13-Week Price Return6.49%
Total Debt / Equity (Annual)21.68x
Current Ratio (Quarterly)1.05x
Enterprise Value$124.902
Revenue / Share Growth (5Y)-30.59%
Asset Turnover (TTM)0.49x
Book Value / Share Growth (5Y)-52.97%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-49.92%
Cash / Share (Annual)$0.17
3-Month Return Std Dev90.29%
Gross Margin (5Y Avg)37.11%
Net Income / Employee (TTM)$-0
ROE (Last FY)-613.49%
Net Interest Coverage (Annual)-2.20x
EPS Basic Excl Extra (Annual)$-0.09
P/FCF (TTM)22.58x
Receivables Turnover (TTM)3.48x
Total Debt / Equity (Quarterly)8.73x
EPS Incl Extra (TTM)$-0.11
Receivables Turnover (Annual)4.91x
ROI (TTM)-24.46%
P/S Ratio (TTM)0.28x
Pretax Margin (5Y Avg)-38.76%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)2.94%
Year-to-Date Return-5.65%
5-Day Price Return6.76%
EPS Normalized (Annual)$-0.09
ROA (5Y Avg)-23.97%
Net Profit Margin (Annual)-51.64%
Month-to-Date Return38.04%
Cash Flow / Share (TTM)$-1.26
EBITD / Share (Annual)$-0.06
Operating Margin (Annual)-34.38%
LT Debt / Equity (Annual)17.40x
ROI (5Y Avg)-22.34%
LT Debt / Equity (Quarterly)8.70x
EPS Basic Excl Extra (TTM)$-0.11
P/TBV (Quarterly)281.74x
P/B Ratio (Annual)5.27x
Inventory Turnover (TTM)1.52x
Pretax Margin (TTM)-70.95%
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)3.62%
Beta1.11x
P/FCF (Annual)3.05x
Revenue / Share (TTM)$0.13
ROE (TTM)-166.14%
52-Week Low$0.50
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TRIBTrinity Biotech plc | 0.28x | -15.76% | 33.81% | — | $0.74 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
About
Trinity Biotech develops and manufactures clinical diagnostic products for laboratory and point-of-care testing, focusing on detection of autoimmune, infectious, and sexually transmitted diseases, as well as diabetes and organ-specific disorders. The company also supplies raw materials to the global life sciences and research industries. The Americas segment accounts for the majority of revenue.